Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1956 2
1957 2
1958 2
1959 1
1960 2
1964 1
1977 1
1980 7
1981 4
1982 1
1983 2
1984 2
1985 4
1986 3
1987 2
1988 1
1989 1
1990 1
1993 1
1995 1
1996 1
1997 1
1998 2
1999 6
2000 2
2001 4
2002 1
2003 4
2004 4
2005 3
2006 4
2007 2
2008 6
2009 5
2010 5
2011 12
2012 5
2013 5
2014 6
2015 4
2016 9
2017 8
2018 6
2019 4
2020 3
2021 5
2022 5
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Results by year

Filters applied: . Clear all
Page 1
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A, Haber L, Kelly MP, Vazzana K, Canova L, Ram P, Pawashe A, Finney J, Jalal S, Chiu D, Colleton CA, Garnova E, Makonnen S, Hickey C, Krueger P, DelFino F, Potocky T, Kuhnert J, Godin S, Retter MW, Duramad P, MacDonald D, Olson WC, Fairhurst J, Huang T, Martin J, Lin JC, Smith E, Thurston G, Kirshner JR. Crawford A, et al. Among authors: kirshner jr. Sci Transl Med. 2019 Jun 19;11(497):eaau7534. doi: 10.1126/scitranslmed.aau7534. Sci Transl Med. 2019. PMID: 31217340
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D, Waite JC, Haber L, Crawford A, Hermann A, Ullman E, Slim R, Godin S, Ajithdoss D, Ye X, Wang B, Wu Q, Ramos I, Pawashe A, Canova L, Vazzana K, Ram P, Herlihy E, Ahmed H, Oswald E, Golubov J, Poon P, Havel L, Chiu D, Lazo M, Provoncha K, Yu K, Kim J, Warsaw JJ, Stokes Oristian N, Siao CJ, Dudgeon D, Huang T, Potocky T, Martin J, MacDonald D, Oyejide A, Rafique A, Poueymirou W, Kirshner JR, Smith E, Olson W, Lin J, Thurston G, Sleeman MA, Murphy AJ, Yancopoulos GD. Skokos D, et al. Among authors: kirshner jr. Sci Transl Med. 2020 Jan 8;12(525):eaaw7888. doi: 10.1126/scitranslmed.aaw7888. Sci Transl Med. 2020. PMID: 31915305
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.
Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavaré R, Ullman E, Mao S, Canova L, Sineshchekova O, Finney J, Pawashe A, Patel S, McKay R, Rizvi S, Damko E, Chiu D, Vazzana K, Ram P, Mohrs K, D'Orvilliers A, Xiao J, Makonnen S, Hickey C, Arnold C, Giurleo J, Chen YP, Thwaites C, Dudgeon D, Bray K, Rafique A, Huang T, Delfino F, Hermann A, Kirshner JR, Retter MW, Babb R, MacDonald D, Chen G, Olson WC, Thurston G, Davis S, Lin JC, Smith E. Haber L, et al. Among authors: kirshner jr. Sci Rep. 2021 Jul 13;11(1):14397. doi: 10.1038/s41598-021-93842-0. Sci Rep. 2021. PMID: 34257348 Free PMC article.
A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, Startz T, Kuhnert J, Retter MW, Godin S, Sharma P, Delfino F, Lin J, Smith E, Thurston G, Kirshner JR. DiLillo DJ, et al. Among authors: kirshner jr. Blood Adv. 2021 Mar 9;5(5):1291-1304. doi: 10.1182/bloodadvances.2020002736. Blood Adv. 2021. PMID: 33651100 Free PMC article.
Antibody drug conjugates of cleavable amino-benzoyl-maytansinoids.
Nittoli T, Delfino F, Kelly M, Carosso S, Markotan T, Kunz A, Chen Z, Mao S, Shan J, Navarro E, Zhao F, Makonnen S, Hickey C, Spink J, Olson W, Kirshner JR, Thurston G, Papadopoulos N. Nittoli T, et al. Among authors: kirshner jr. Bioorg Med Chem. 2020 Dec 1;28(23):115785. doi: 10.1016/j.bmc.2020.115785. Epub 2020 Oct 11. Bioorg Med Chem. 2020. PMID: 33099182
Reply to L.B. Marks et al.
Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB. Recht A, et al. Among authors: kirshner jj. J Clin Oncol. 2017 Apr 10;35(11):1258-1259. doi: 10.1200/JCO.2016.71.3966. Epub 2017 Jan 9. J Clin Oncol. 2017. PMID: 28068171 No abstract available.
Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies.
Zhu M, Olson K, Kirshner JR, Khaksar Toroghi M, Yan H, Haber L, Meagher C, Flink DM, Ambati SR, Davis JD, DiCioccio AT, Smith EJ, Retter MW. Zhu M, et al. Among authors: kirshner jr. Clin Transl Sci. 2022 Apr;15(4):954-966. doi: 10.1111/cts.13212. Epub 2022 Jan 7. Clin Transl Sci. 2022. PMID: 34997701 Free PMC article.
155 results